Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 5.5% - What's Next?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report)'s share price was up 5.5% on Wednesday . The stock traded as high as $6.11 and last traded at $5.94. Approximately 8,951,025 shares changed hands during mid-day trading, a decline of 26% from the average daily volume of 12,114,125 shares. The stock had previously closed at $5.63.

Analyst Ratings Changes

Several brokerages recently issued reports on RXRX. Leerink Partners lowered their target price on Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a research report on Friday, February 28th. Cowen restated a "hold" rating on shares of Recursion Pharmaceuticals in a research report on Friday, February 28th. Morgan Stanley reduced their target price on Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating on the stock in a report on Thursday, April 10th. KeyCorp lowered their price target on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating for the company in a report on Wednesday, January 8th. Finally, Needham & Company LLC restated a "buy" rating and issued a $11.00 price target on shares of Recursion Pharmaceuticals in a research report on Tuesday, April 8th. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $8.20.

Recursion Pharmaceuticals Price Performance

The stock has a market capitalization of $2.30 billion, a P/E ratio of -3.75 and a beta of 1.00. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. The business has a fifty day simple moving average of $6.21 and a 200-day simple moving average of $6.78.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last issued its earnings results on Friday, February 28th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The company had revenue of $4.60 million for the quarter, compared to the consensus estimate of $19.04 million. During the same period in the prior year, the company earned ($0.42) earnings per share. The firm's revenue was down 57.8% compared to the same quarter last year. Sell-side analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Institutional Trading of Recursion Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. PDS Planning Inc acquired a new stake in Recursion Pharmaceuticals in the first quarter valued at approximately $69,000. Sequoia Financial Advisors LLC bought a new position in shares of Recursion Pharmaceuticals in the 1st quarter worth $67,000. Cambridge Investment Research Advisors Inc. grew its position in Recursion Pharmaceuticals by 33.1% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 117,120 shares of the company's stock valued at $620,000 after purchasing an additional 29,136 shares during the period. San Luis Wealth Advisors LLC bought a new stake in Recursion Pharmaceuticals during the 1st quarter valued at $54,000. Finally, QRG Capital Management Inc. raised its holdings in Recursion Pharmaceuticals by 8.5% during the first quarter. QRG Capital Management Inc. now owns 28,515 shares of the company's stock worth $151,000 after buying an additional 2,244 shares during the last quarter. 89.06% of the stock is owned by institutional investors.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.